Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer

PURPOSE: Immune checkpoint inhibitors (ICIs) are effective in only a minority of patients with esophagogastric cancer (EGC). Here, we aimed to identify predictors of durable clinical benefit to ICI in EGC. EXPERIMENTAL DESIGN: Patients with advanced EGC treated with ICIs at Memorial Sloan Kettering...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Greally, Megan, Chou, Joanne F., Chatila, Walid K., Margolis, Matthew, Capanu, Marinela, Hechtman, Jaclyn F., Tuvy, Yaelle, Kundra, Ritika, Daian, Foysal, Ladanyi, Marc, Kelsen, David P., Ilson, David H., Berger, Michael F., Tang, Laura H., Solit, David B., Diaz, Luis A., Schultz, Nikolaus, Janjigian, Yelena Y., Ku, Geoffrey Y.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905384/
https://ncbi.nlm.nih.gov/pubmed/31337644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3603
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars